Chemical inhibitors of angiotensin I converting enzyme 3 (ACE3) operate through a variety of mechanisms, all of which converge on the common outcome of inhibiting the enzyme's ability to convert angiotensin I to the potent vasoconstrictor, angiotensin II. These inhibitors, such as Captopril, Enalapril, and Lisinopril, achieve this through competitive binding to the enzyme's active site. This site, which normally accommodates angiotensin I, becomes occupied by these inhibitors, thereby blocking the substrate's access and preventing its conversion. Captopril, for instance, binds directly to the active site, offering immediate inhibition. Enalapril, on the other hand, serves as a prodrug that metabolizes into enalaprilat before exerting its inhibitory effects. Similarly, Lisinopril competes with angiotensin I, effectively reducing angiotensin II production and its vasoconstrictive effects.
Other inhibitors such as Ramipril, Quinapril, and Fosinopril also inhibit ACE3 by binding to the zinc-containing active site of the enzyme. For instance, Ramipril is metabolized into ramiprilat which then inhibits ACE3, while Quinapril and Fosinopril engage in reversible binding to the enzyme to exert their inhibitory action. Furthermore, inhibitors like Perindopril, Trandolapril, and Benazepril are metabolized into their active forms (perindoprilat, trandolaprilat, and benazeprilat, respectively) and inhibit ACE3 by competitively binding to the enzyme's active site. This competitive binding ensures that angiotensin I cannot be converted to angiotensin II, thereby inhibiting the enzyme's function. Lastly, Moexipril, Spirapril, and Imidapril, after being converted to their active metabolites (moexiprilat, spiraprilat, and imidaprilat), bind to the active site of ACE3, preventing the production of angiotensin II and consequently inhibiting the enzyme's activity. Each of these chemicals ensures that the function of ACE3 is inhibited, which centers on the blockade of angiotensin II production, a key regulator of vasoconstriction.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Captopril | 62571-86-2 | sc-200566 sc-200566A | 1 g 5 g | $49.00 $91.00 | 21 | |
Captopril inhibits the angiotensin I converting enzyme 3 (ACE3) by binding to its active site, thereby preventing the conversion of angiotensin I to angiotensin II, a potent vasoconstrictor. | ||||||
Ramipril | 87333-19-5 | sc-205833 sc-205833A sc-205833B sc-205833C sc-205833D | 500 mg 1 g 2 g 5 g 10 g | $179.00 $245.00 $364.00 $733.00 $1254.00 | 1 | |
Ramipril, in its active form ramiprilat, inhibits ACE3 by binding to its active site, effectively decreasing the conversion of angiotensin I to angiotensin II. | ||||||
Quinapril Hydrochloride | 82586-55-8 | sc-205829 sc-205829A | 100 mg 500 mg | $150.00 $450.00 | ||
Quinapril inhibits ACE3 by reversibly binding to the enzyme's active site, which prevents angiotensin II formation and its subsequent blood pressure-raising effects. | ||||||
Perindopril | 82834-16-0 | sc-205799 sc-205799A sc-205799B | 100 mg 250 mg 1 g | $128.00 $255.00 $683.00 | 1 | |
Perindopril acts as an ACE3 inhibitor by competitive inhibition at the active site of the enzyme, thereby lowering the production of angiotensin II. | ||||||